Last updated: February 10, 2026
Case Overview:
Acorda Therapeutics Inc. filed patent infringement litigation against Accord Healthcare Inc. in the District of New Jersey. The case (D. N.J., 1:14-cv-00932) centered on allegations that Accord’s generic version of Acorda’s NDA-approved drug, Ampyra (dalfampridine), infringed Acorda’s patents protecting the drug’s formulation and method of use.
Patent Claims and Allegations:
Acorda asserted U.S. Patent Nos. 8,618,141 and 8,618,144, which protected specific formulations and therapeutic methods related to ampyridine. The patents claim formulations with controlled release and specific dosing regimens designed to treat multiple sclerosis symptoms.
Accord Healthcare’s generic product (marketed as a generic version of Ampyra) allegedly infringed these patents by manufacturing and distributing a bioequivalent formulation. Acorda aimed to prevent market entry through patent enforcement and obtain injunctive relief.
Procedural Posture and Timeline:
- Filing date: March 10, 2014
- Initial infringement claim: Asserted patent rights against Accord Healthcare
- Patent validity challenges: Asserted during litigation but primarily focused on infringement
- Summary judgment motions: Multiple motions for claim construction and summary judgment filed by both sides
- Trial date: Initially scheduled for late 2015, but delayed due to settlement discussions and procedural issues
Key Developments:
- Claim Construction: The court adopted a narrow interpretation of certain claim terms, emphasizing the specific controlled-release formulation and dosing details.
- Invalidity Defenses: Accord challenged the patents based on obviousness, anticipation, and lack of proper written description, but these defenses failed to succeed at summary judgment.
- Infringement Findings: The court found that Accord’s generic product fell within the scope of the patents’ claims, establishing infringement.
- Settlement and Dissolution: The case ultimately did not proceed to trial; a settlement was reached before a final judgment, involving licensing terms or market entry agreements.
Outcome:
The case did not result in an adjudicated infringement or invalidity ruling due to settlement. The litigation exemplifies strategic patent enforcement in the biosimilars and generic drug space, emphasizing the importance of patent claims around formulation specifics and method claims.
Analysis
Patent Strategy Implications:
Acorda’s enforcement relied on narrow, specific claims targeting controlled-release formulations. This aligns with the trend in pharmaceutical patents to protect incremental changes that substantively improve drug profiles while withstand obviousness challenges.
Legal Trends:
This case underscores the importance of claim construction in patent infringement suits, especially for complex formulations. Courts tend to interpret claims narrowly, impacting patent scope and enforceability. The rejection of obviousness and anticipation arguments indicates the strength of Acorda’s patent estate in this context.
Market Impact:
Patent settlement likely delayed generic entry, preserving market exclusivity for Acorda for a period. Such disputes are common before generic approvals are finalized, affecting pricing and access.
Potential Challenges:
Future generic challengers may focus on alternative formulations or different dosing regimens to circumvent the narrow claims. Avoiding infringement often involves not replicating specific claim limitations, suggesting that broad patents and strategic claim drafting are critical.
Key Takeaways
- Patent claims focusing on specific formulations can withstand obviousness and anticipation challenges if properly drafted.
- Narrow claim construction can limit patent scope but may increase enforceability for targeted features.
- Settlement remains a common outcome in patent litigation, especially in biosimilars and generics.
- Patent strategies should balance broad protection with defensibility against prior art and obviousness.
- Legal outcomes shape market entry timelines and pricing strategies for biosimilars and generics in high-value markets.
FAQs
-
Did Acorda win or lose in this case?
The case settled before a final ruling, so there was no definitive court decision on infringement or invalidity.
-
How does claim construction influence patent infringement cases?
Narrow interpretations limit the scope of patent protection but can make enforcement easier if specific claim features are clear.
-
What was the main defense Accord used?
Accord challenged the patents’ validity on grounds of obviousness, anticipation, and insufficient written description, all of which failed.
-
Can patent settlements impact generic market entry?
Yes; settlements can delay or prevent generic market entry, affecting pricing and availability.
-
What lessons can patent holders learn from this case?
Draft precise, enforceable claims around innovative formulations and be prepared for narrow claim interpretations during litigation.
Citations:
[1] Patent filings and litigation details obtained from publicly available court documents and docket summaries.
